Targovax KOL Lunch London June 2017

London, June 26, 2017

Developing two complementary approaches; a peptide-based immunotherapy platform for patients with RAS-mutated cancers and a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors.

Register / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Targovax [TRVX:OS] NKr836 MM MCap
2 com­ple­men­tary ap­proach­es: (1) RAS neo-anti­gen vaccine for pa­tients with RAS-me­di­at­ed can­cers: Ph 1/2 and Ph 1b trials on­go­ing w/2 da­ta read­outs in 2018 and (2) virus-based I-O plat­form (en­gi­neered... [more in­for­ma­tion]